Sun Pharma's US pact may reshape India's pharma playbook

Sun Pharma has agreed to offer 'Most Favoured Nation' pricing to US Medicaid programmes in exchange for a delay in Section 232 tariffs on its innovative medicines. The agreement shows how pricing, onshoring and market access are reshaping strategy for Indian drugmakers in America.Donald Trump led US wants cheaper medicines. But it also wants pharmaceutical companies to make more of those medicines closer to home. And that is where Sun Pharma’s latest agreement with the US administration becomes important – not just for India’s largest drugmaker, but for the wider Indian pharmaceutical industry.Sun Pharmaceutical Industries has agreed to extend Most Favoured Nation (MFN) pricing to US state Medicaid programmes and to apply MFN pricing to future innovative medicine launches.In simple terms, the US wants Medicaid - the government-backed health insurance programme serving millions of low-income Americans – to get drug prices comparable to the lowest prices available in other developed countries.In return, Sun gets a significant concession. The US will delay Section 232 tariffs on its innovative pharmaceutical products for more than two years. The exact commercial terms of the agreement have not been disclosed. That trade-off is important because Sun is no longer simply an Indian company exporting low-cost generic medicines to America. Its US business has increasingly shifted towards higher-value medicines in areas such as dermatology, immunology, oncology and ophthalmology.The US accounts for about 27% of Sun Pharma’s global revenue and is its biggest market for innovative medicines. The timing also matters.Earlier this year, Sun agreed to acquire US-based Organon at an enterprise value of $11.75 billion, giving it a much larger portfolio of branded medicines, women's health products and biosimilars. That makes its long-term exposure to the American healthcare market considerably bigger.A BIGGER US BETFor Sun, therefore, the MFN agreement is about more than simply accepting lower prices.MFN pricing can mean that medicines supplied through Medicaid have to be offered at much lower prices than they might otherwise command. That could put pressure on margins – the amount a company earns after accounting for costs.Shrikant Akolkar, veteran pharma analyst with Nuvama Institutional Equities, described Medicaid sales as potentially a “low margin proposal”, although he also pointed to the benefit of reaching more patients.That is the central balancing act for Sun: accepting pricing pressure in one part of the market in exchange for greater access, fewer tariff risks and potentially more predictable operating conditions in the US.Another senior pharma analyst, Salil Kallianpur, sees the agreement in the larger context of the Organon acquisition. He said the deal could provide “policy certainty” as Sun integrates Organon and expands its American footprint.That could become increasingly valuable because Washington is changing the rules of the pharmaceutical game. The US administration has been pushing two ideas simultaneously: medicines should become cheaper for Americans, and pharmaceutical supply chains should become less dependent on overseas manufacturing.The Section 232 measures are part of that broader strategy.The US has treated dependence on imported pharmaceuticals and active pharmaceutical ingredients – the chemical ingredients that actually make a medicine work – as a national-security concern. Under its current policy, companies that enter qualifying MFN and onshoring arrangements can receive preferential tariff treatment.Generic medicines, however, are currently excluded from the Section 232 tariffs.This distinction matters for India because generics remain the backbone of the country's pharmaceutical relationship with America.Indian companies supplied around 47% of US generic prescriptions, according to industry data, while India's pharmaceutical exports to the US reached about $8.7 billion in FY2023-24, making America India's largest pharmaceutical export market.For decades, the basic business model has been relatively straightforward: manufacture medicines efficiently in India, where production costs can be competitive, and export them to the US, one of the world's largest healthcare markets.But that equation is now being rewritten.INDIA’S PHARMA MODEL SHIFTSThe bigger message from Sun's agreement is that cost competitiveness alone may not be enough to win in the US market in the years ahead.The US is increasingly looking at where medicines and their ingredients are manufactured, how secure those supplies are and whether companies are willing to invest in production there. The White House said the nine companies covered by its latest round of agreements have collectively committed at least $19.6 billion towards US manufacturing.For Indian drugmakers, this creates both a challenge and an opportunity.The challenge is obvious. If more production has to move to the US, Indian companies could lose some of the cost advantage created by manufacturing at scale in India. Building plants, hiring workers and maintaining supply chains in America is considerably more expensive than doing the same in India.But there is another way of looking at it.Indian pharmaceutical companies could increasingly develop a dual manufacturing model – retaining India as a major base for research, APIs, generic medicines and large-scale production while building or expanding manufacturing and commercial capabilities in the US for medicines that need local supply.That is essentially the emerging equation analysts see in Sun's strategy: India for cost and scale, America for strategic manufacturing and market access.And Sun's position makes it an important test case. Its US business already includes manufacturing, sales and marketing, clinical development and both API and finished-product production. The company itself has highlighted the US as a key area of investment and expansion.The Organon acquisition makes this shift even more significant. Sun will have a substantially larger presence in branded pharmaceuticals and biosimilars, areas where the economics are very different from traditional generics.For the rest of Indian pharma, this could influence how companies think about their own US strategies. Larger players with significant American exposure may have to weigh local manufacturing, acquisitions and partnerships against the cost advantages of continuing to export from India.There is also a potential upside for India. If companies expand their US footprint without abandoning Indian manufacturing, India could remain the industry's global production and supply-chain hub while American facilities become an additional layer of market access.But the risk is that more value-added manufacturing gradually moves overseas.That is why Sun's agreement should not be viewed simply as a deal between one company and the Trump administration. It reflects a much larger transformation in the world's biggest pharmaceutical market.For American policymakers, the priority is cheaper medicines and greater domestic supply security. For Sun, it is about protecting access to a market that already generates a significant share of its revenue while it makes its biggest global acquisition yet.For India, the stakes are bigger.The country's pharma industry has built its global reputation on being able to manufacture quality medicines at competitive prices. The next phase may require something more: global manufacturing networks, stronger innovative portfolios and the ability to navigate increasingly political pharmaceutical supply chains.Sun's deal suggests that the old formula – make in India, sell in America – is evolving.The future could increasingly be 'make efficiently in India, manufacture strategically in America, and sell globally'. And that could reshape how India's pharmaceutical industry competes in the US for years to come.- EndsPublished On: Sep 1, 2026 16:55 IST